Cargando…

The distribution of BRAF gene fusions in solid tumors and response to targeted therapy

Although the BRAF V600E base substitution is an approved target for the BRAF inhibitors in melanoma, BRAF gene fusions have not been investigated as anticancer drug targets. In our study, a wide variety of tumors underwent comprehensive genomic profiling for hundreds of known cancer genes using the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ross, Jeffrey S., Wang, Kai, Chmielecki, Juliann, Gay, Laurie, Johnson, Adrienne, Chudnovsky, Jacob, Yelensky, Roman, Lipson, Doron, Ali, Siraj M, Elvin, Julia A., Vergilio, Jo‐Anne, Roels, Steven, Miller, Vincent A, Nakamura, Brooke N., Gray, Adam, Wong, Michael K, Stephens, Philip J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Cancer Genetics and Epigenetics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5049644/ https://www.ncbi.nlm.nih.gov/pubmed/26314551 http://dx.doi.org/10.1002/ijc.29825

Ejemplares similares

A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy
por: Williams, Casey B, et al.
Publicado: (2015)

Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification
por: Disel, Umut, et al.
Publicado: (2015)

Comprehensive genomic profiling identifies a novel TNKS2–PDGFRA fusion that defines a myeloid neoplasm with eosinophilia that responded dramatically to imatinib therapy
por: Chalmers, Z R, et al.
Publicado: (2015)

CpG island methylator phenotype identifies high risk patients among microsatellite stable BRAF mutated colorectal cancers
por: Vedeld, Hege Marie, et al.
Publicado: (2017)

Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib
por: Ali, Siraj M., et al.
Publicado: (2014)

Identification of novel cyclin gene fusion transcripts in endometrioid ovarian carcinomas
por: Agostini, Antonio, et al.
Publicado: (2018)

The association between bromodomain proteins and cancer stemness in different solid tumor types
por: Czerwinska, Patrycja, et al.
Publicado: (2022)

Regulatory networks and 5′ partner usage of miRNA host gene fusions in breast cancer
por: Hafstað, Völundur, et al.
Publicado: (2022)

Identification of novel BRCA founder mutations in Middle Eastern breast cancer patients using capture and Sanger sequencing analysis
por: Bu, Rong, et al.
Publicado: (2016)

Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies
por: Ross, J S, et al.
Publicado: (2014)

Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer
por: Ross, J S, et al.
Publicado: (2014)

BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma
por: Paoluzzi, Luca, et al.
Publicado: (2016)

Quantitative analysis of somatically acquired and constitutive uniparental disomy in gastrointestinal cancers
por: Torabi, Keyvan, et al.
Publicado: (2018)

AGK‐BRAF gene fusion is a recurrent event in sporadic pediatric thyroid carcinoma
por: Cordioli, Maria Isabel C. V., et al.
Publicado: (2016)

A novel, potentially targetable TMEM106B-BRAF fusion in pleomorphic xanthoastrocytoma
por: Hsiao, Susan J., et al.
Publicado: (2017)

Using linkage studies combined with whole‐exome sequencing to identify novel candidate genes for familial colorectal cancer
por: Toma, Claudio, et al.
Publicado: (2019)

STUMP un“stumped”: anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion
por: Subbiah, Vivek, et al.
Publicado: (2015)

AKT1 and BRAF mutations in pediatric aggressive fibromatosis
por: Meazza, Cristina, et al.
Publicado: (2016)

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
por: Chalmers, Zachary R., et al.
Publicado: (2017)

Suppression of pancreatic cancer growth and metastasis by HMP19 identified through genome‐wide shRNA screen
por: Kurahara, Hiroshi, et al.
Publicado: (2016)

Genetic and epigenetic aberrations occurring in colorectal tumors associated with serrated pathway
por: Sakai, Eiji, et al.
Publicado: (2015)

Molecular differences in the microsatellite stable phenotype between left‐sided and right‐sided colorectal cancer
por: Takahashi, Yayoi, et al.
Publicado: (2016)

A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cells
por: Hvichia, G.E., et al.
Publicado: (2016)

FANCM c.5101C>T mutation associates with breast cancer survival and treatment outcome
por: Kiiski, Johanna I., et al.
Publicado: (2016)

Neuroblastoma cells undergo transcriptomic alterations upon dissemination into the bone marrow and subsequent tumor progression
por: Rifatbegovic, Fikret, et al.
Publicado: (2017)

Single CpG hypermethylation, allele methylation errors, and decreased expression of multiple tumor suppressor genes in normal body cells of mutation‐negative early‐onset and high‐risk breast cancer patients
por: Böck, Julia, et al.
Publicado: (2018)

Distinct methylation profile of mucinous ovarian carcinoma reveals susceptibility to proteasome inhibitors
por: Liew, Phui‐Ly, et al.
Publicado: (2018)

Gene–environment interactions involving functional variants: Results from the Breast Cancer Association Consortium
por: Barrdahl, Myrto, et al.
Publicado: (2017)

Characteristics of genomic alterations of lung adenocarcinoma in young never‐smokers
por: Luo, Wenxin, et al.
Publicado: (2018)

Fountain of youth for squamous cell carcinomas? On the epigenetic age of non‐small cell lung cancer and corresponding tumor‐free lung tissues
por: Marwitz, Sebastian, et al.
Publicado: (2018)

Targeted RNA‐seq successfully identifies normal and pathogenic splicing events in breast/ovarian cancer susceptibility and Lynch syndrome genes
por: Brandão, Rita D., et al.
Publicado: (2019)

Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC
por: Wang, Jinguang, et al.
Publicado: (2018)

Detection of circulating microRNAs with Ago2 complexes to monitor the tumor dynamics of colorectal cancer patients during chemotherapy
por: Fuji, Tomokazu, et al.
Publicado: (2019)

Multigene panel sequencing of established and candidate melanoma susceptibility genes in a large cohort of Dutch non‐CDKN2A/CDK4 melanoma families
por: Potjer, Thomas P., et al.
Publicado: (2019)

Genetic variants in SLC22A3 contribute to the susceptibility to colorectal cancer
por: Ren, Anjing, et al.
Publicado: (2019)

Hypermutagenesis in untreated adult gliomas due to inherited mismatch mutations
por: Sa, Jason K., et al.
Publicado: (2019)

ANO7 is associated with aggressive prostate cancer
por: Kaikkonen, Elina, et al.
Publicado: (2018)

Genetic susceptibility in the development of colorectal adenomas according to family history of colorectal cancer
por: Gargallo, Carla J., et al.
Publicado: (2018)

Inhibiting homologous recombination decreases extrachromosomal amplification but has no effect on intrachromosomal amplification in methotrexate‐resistant colon cancer cells
por: Cai, Mengdi, et al.
Publicado: (2018)

Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing
por: Girard, Elodie, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_711jcb8644utg4qijl6pgosee4